AstraZeneca PLC (AZN)
USD 64.64
(-3.78%)
USD 64.64
(-3.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.95 Billion USD | 81.11% |
| 2022 | 3.28 Billion USD | 2835.71% |
| 2021 | 112 Million USD | -96.5% |
| 2020 | 3.19 Billion USD | 139.4% |
| 2019 | 1.33 Billion USD | -38.05% |
| 2018 | 2.15 Billion USD | -28.19% |
| 2017 | 3 Billion USD | -14.23% |
| 2016 | 3.49 Billion USD | 23.86% |
| 2015 | 2.82 Billion USD | 129.12% |
| 2014 | 1.23 Billion USD | -51.76% |
| 2013 | 2.55 Billion USD | -59.41% |
| 2012 | 6.29 Billion USD | -36.92% |
| 2011 | 9.98 Billion USD | 23.97% |
| 2010 | 8.05 Billion USD | 7.07% |
| 2009 | 7.52 Billion USD | 23.27% |
| 2008 | 6.1 Billion USD | 9.04% |
| 2007 | 5.59 Billion USD | -7.41% |
| 2006 | 6.04 Billion USD | 28.41% |
| 2005 | 4.7 Billion USD | 28.44% |
| 2004 | 3.66 Billion USD | 20.69% |
| 2003 | 3.03 Billion USD | 7.0% |
| 2002 | 2.83 Billion USD | -31.73% |
| 2001 | 4.15 Billion USD | 63.59% |
| 2000 | 2.54 Billion USD | 122.39% |
| 1999 | 1.14 Billion USD | -3.6% |
| 1998 | 1.18 Billion USD | -1.79% |
| 1997 | 1.2 Billion USD | 9.59% |
| 1996 | 1.1 Billion USD | 112.09% |
| 1995 | 519.19 Million USD | -25.04% |
| 1994 | 692.58 Million USD | 8.64% |
| 1993 | 637.53 Million USD | 425.43% |
| 1992 | 121.33 Million USD | -81.2% |
| 1991 | 645.55 Million USD | 50.75% |
| 1990 | 428.22 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.92 Billion USD | -11.56% |
| 2024 Q1 | 2.17 Billion USD | 126.98% |
| 2023 Q3 | 1.37 Billion USD | -24.42% |
| 2023 Q4 | 960 Million USD | -30.13% |
| 2023 FY | 5.95 Billion USD | 81.11% |
| 2023 Q1 | 1.8 Billion USD | 100.11% |
| 2023 Q2 | 1.81 Billion USD | 0.83% |
| 2022 Q4 | 901 Million USD | -45.06% |
| 2022 Q2 | 360 Million USD | -6.74% |
| 2022 FY | 3.28 Billion USD | 2835.71% |
| 2022 Q3 | 1.64 Billion USD | 355.56% |
| 2022 Q1 | 386 Million USD | 211.24% |
| 2021 Q4 | -347 Million USD | 79.0% |
| 2021 FY | 112 Million USD | -96.5% |
| 2021 Q1 | 1.56 Billion USD | 54.25% |
| 2021 Q2 | 550 Million USD | -64.77% |
| 2021 Q3 | -1.65 Billion USD | -400.36% |
| 2020 Q2 | 756 Million USD | -3.08% |
| 2020 FY | 3.19 Billion USD | 139.4% |
| 2020 Q1 | 780 Million USD | 149.2% |
| 2020 Q3 | 648 Million USD | -14.29% |
| 2020 Q4 | 1.01 Billion USD | 56.17% |
| 2019 Q1 | 593 Million USD | -42.65% |
| 2019 FY | 1.33 Billion USD | -38.05% |
| 2019 Q4 | 313 Million USD | 4.68% |
| 2019 Q3 | 299 Million USD | 130.0% |
| 2019 Q2 | 130 Million USD | -78.08% |
| 2018 FY | 2.15 Billion USD | -28.19% |
| 2018 Q1 | 340 Million USD | -73.87% |
| 2018 Q2 | 350 Million USD | 2.94% |
| 2018 Q3 | 431 Million USD | 23.14% |
| 2018 Q4 | 1.03 Billion USD | 139.91% |
| 2017 Q3 | 686 Million USD | 43.82% |
| 2017 FY | 3 Billion USD | -14.23% |
| 2017 Q4 | 1.3 Billion USD | 89.65% |
| 2017 Q2 | 477 Million USD | -11.17% |
| 2017 Q1 | 537 Million USD | -70.85% |
| 2016 Q4 | 1.84 Billion USD | 81.66% |
| 2016 FY | 3.49 Billion USD | 23.86% |
| 2016 Q2 | -3 Million USD | -100.46% |
| 2016 Q1 | 646 Million USD | -20.05% |
| 2016 Q3 | 1.01 Billion USD | 33900.0% |
| 2015 Q3 | 770 Million USD | 10.47% |
| 2015 Q2 | 697 Million USD | 26.73% |
| 2015 FY | 2.82 Billion USD | 129.12% |
| 2015 Q4 | 808 Million USD | 4.94% |
| 2015 Q1 | 550 Million USD | 271.34% |
| 2014 Q2 | 796 Million USD | 57.94% |
| 2014 Q3 | 254 Million USD | -68.09% |
| 2014 FY | 1.23 Billion USD | -51.76% |
| 2014 Q1 | 504 Million USD | 196.18% |
| 2014 Q4 | -321 Million USD | -226.38% |
| 2013 Q3 | 1.24 Billion USD | 51.4% |
| 2013 Q2 | 823 Million USD | -18.6% |
| 2013 FY | 2.55 Billion USD | -59.41% |
| 2013 Q1 | 1.01 Billion USD | -33.53% |
| 2013 Q4 | -524 Million USD | -142.05% |
| 2012 Q4 | 1.52 Billion USD | 0.66% |
| 2012 Q3 | 1.51 Billion USD | -5.39% |
| 2012 Q1 | 1.62 Billion USD | 9.35% |
| 2012 FY | 6.29 Billion USD | -36.92% |
| 2012 Q2 | 1.59 Billion USD | -1.72% |
| 2011 Q3 | 3.47 Billion USD | 64.55% |
| 2011 FY | 9.98 Billion USD | 23.97% |
| 2011 Q4 | 1.48 Billion USD | -57.26% |
| 2011 Q2 | 2.11 Billion USD | -27.31% |
| 2011 Q1 | 2.9 Billion USD | 79.33% |
| 2010 Q4 | 1.62 Billion USD | 4.72% |
| 2010 FY | 8.05 Billion USD | 7.07% |
| 2010 Q1 | 2.77 Billion USD | 78.82% |
| 2010 Q3 | 1.54 Billion USD | -26.53% |
| 2010 Q2 | 2.1 Billion USD | -24.13% |
| 2009 FY | 7.52 Billion USD | 23.27% |
| 2009 Q3 | 2.11 Billion USD | 23.9% |
| 2009 Q4 | 1.55 Billion USD | -26.57% |
| 2009 Q1 | 2.14 Billion USD | 71.96% |
| 2009 Q2 | 1.7 Billion USD | -20.46% |
| 2008 Q1 | 1.5 Billion USD | 18.72% |
| 2008 Q3 | 1.73 Billion USD | 6.79% |
| 2008 Q4 | 1.24 Billion USD | -27.86% |
| 2008 Q2 | 1.62 Billion USD | 7.78% |
| 2008 FY | 6.1 Billion USD | 9.04% |
| 2007 Q3 | 1.34 Billion USD | -5.82% |
| 2007 Q4 | 1.26 Billion USD | -5.73% |
| 2007 Q2 | 1.42 Billion USD | -8.59% |
| 2007 FY | 5.59 Billion USD | -7.41% |
| 2007 Q1 | 1.56 Billion USD | 8.94% |
| 2006 Q3 | 1.58 Billion USD | -0.75% |
| 2006 Q2 | 1.59 Billion USD | 12.29% |
| 2006 Q1 | 1.42 Billion USD | 16.34% |
| 2006 FY | 6.04 Billion USD | 28.41% |
| 2006 Q4 | 1.43 Billion USD | -9.77% |
| 2005 Q2 | 1.21 Billion USD | 17.21% |
| 2005 Q4 | 1.22 Billion USD | 0.08% |
| 2005 Q3 | 1.22 Billion USD | 0.33% |
| 2005 Q1 | 1.04 Billion USD | -2.99% |
| 2005 FY | 4.7 Billion USD | 28.44% |
| 2004 Q2 | 811 Million USD | 1.76% |
| 2004 Q4 | 1.07 Billion USD | -5.38% |
| 2004 Q3 | 1.13 Billion USD | 39.7% |
| 2004 FY | 3.66 Billion USD | 20.69% |
| 2004 Q1 | 797 Million USD | 25.51% |
| 2003 Q1 | 933.53 Million USD | 115.45% |
| 2003 FY | 3.03 Billion USD | 7.0% |
| 2003 Q4 | 635 Million USD | -20.48% |
| 2003 Q3 | 798.54 Million USD | 19.38% |
| 2003 Q2 | 668.91 Million USD | -28.35% |
| 2002 FY | 2.83 Billion USD | -31.73% |
| 2002 Q4 | 433.29 Million USD | -34.33% |
| 2002 Q2 | 775 Million USD | -19.1% |
| 2002 Q1 | 958 Million USD | -51.41% |
| 2002 Q3 | 659.82 Million USD | -14.86% |
| 2001 Q2 | 686 Million USD | -12.1% |
| 2001 Q4 | 1.97 Billion USD | 177.32% |
| 2001 Q3 | 711 Million USD | 3.64% |
| 2001 FY | 4.15 Billion USD | 63.59% |
| 2001 Q1 | 780.46 Million USD | 42.09% |
| 2000 Q1 | 661.14 Million USD | 480.93% |
| 2000 Q3 | 651.17 Million USD | -4.1% |
| 2000 Q4 | 549.27 Million USD | -15.65% |
| 2000 FY | 2.54 Billion USD | 122.39% |
| 2000 Q2 | 679.02 Million USD | 2.7% |
| 1999 Q1 | 416 Million USD | 102.97% |
| 1999 FY | 1.14 Billion USD | -3.6% |
| 1999 Q2 | 416 Million USD | 0.0% |
| 1999 Q3 | 484 Million USD | 16.35% |
| 1999 Q4 | -173.56 Million USD | -135.86% |
| 1998 FY | 1.18 Billion USD | -1.79% |
| 1998 Q3 | 233.4 Million USD | -36.23% |
| 1998 Q1 | 366 Million USD | 13.82% |
| 1998 Q4 | 204.96 Million USD | -12.18% |
| 1998 Q2 | 366 Million USD | 0.0% |
| 1997 Q4 | 321.57 Million USD | 8.97% |
| 1997 Q1 | 372.5 Million USD | -40.88% |
| 1997 Q3 | 295.1 Million USD | -20.78% |
| 1997 FY | 1.2 Billion USD | 9.59% |
| 1997 Q2 | 372.5 Million USD | 0.0% |
| 1996 FY | 1.1 Billion USD | 112.09% |
| 1996 Q2 | 315 Million USD | 0.0% |
| 1996 Q3 | 235.6 Million USD | -25.21% |
| 1996 Q4 | 630.04 Million USD | 167.42% |
| 1996 Q1 | 315 Million USD | 160.35% |
| 1995 Q3 | 132.7 Million USD | -50.76% |
| 1995 Q1 | 269.4 Million USD | -17.64% |
| 1995 FY | 519.19 Million USD | -25.04% |
| 1995 Q4 | 120.99 Million USD | -8.82% |
| 1995 Q2 | 269.5 Million USD | 0.04% |
| 1994 Q1 | 193.7 Million USD | 58.08% |
| 1994 Q2 | 348.1 Million USD | 79.71% |
| 1994 Q4 | 327.08 Million USD | 88.74% |
| 1994 FY | 692.58 Million USD | 8.64% |
| 1994 Q3 | 173.3 Million USD | -50.22% |
| 1993 Q3 | 136 Million USD | -28.23% |
| 1993 Q4 | 122.53 Million USD | -9.9% |
| 1993 Q1 | 189.5 Million USD | 0.0% |
| 1993 Q2 | 189.5 Million USD | 0.0% |
| 1993 FY | 637.53 Million USD | 425.43% |
| 1992 FY | 121.33 Million USD | -81.2% |
| 1991 FY | 645.55 Million USD | 50.75% |
| 1990 FY | 428.22 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Amgen Inc. | 6.71 Billion USD | 11.344% |
| Biogen Inc. | 1.16 Billion USD | -412.876% |
| Gilead Sciences, Inc. | 5.66 Billion USD | -5.119% |
| MIRA Pharmaceuticals, Inc. | -11.98 Million USD | 49798.127% |
| Scilex Holding Company | -114.33 Million USD | 5308.561% |
| Scilex Holding Company | -114.33 Million USD | 5308.561% |